MOTS-c
A mitochondrial-derived peptide being researched for metabolic signaling, energy regulation, and healthy aging.
OVERVIEW
MOTS-c is a mitochondrial-derived peptide involved in cellular metabolic signaling. Research interest includes insulin sensitivity, metabolic flexibility, and exercise-related physiology, but it is not an FDA-approved drug.
Proposed Mechanisms
• Proposed AMPK activation • Metabolic signaling • Mitochondrial function • Metabolic flexibility
Potential Applications
• Metabolic-health research • Weight-management research • Exercise-performance research • Longevity research
Pharmacokinetics
Reliable human pharmacokinetic parameters are not established in the source material.
Dosing
No FDA-approved human dosing. The source draft listed 5–15 mg two or three times weekly; this is an investigational protocol reference, not a recommendation.
Monitoring
No standardized clinical monitoring protocol; research protocols may assess metabolic markers and adverse effects.
Side Effects
Human safety data are insufficiently characterized.
Contraindications
No FDA-approved labeling or established contraindication profile; clinician review is required.
FDA/Investigational Status
Not FDA-approved. FDA states that it has not identified human-exposure data for compounded MOTS-c and lacks sufficient information to know whether it may cause harm. FDA advisory review does not constitute approval.
Disclaimer/Notes
Educational resource only. Do not state or imply proven effects on weight, insulin sensitivity, or longevity.
Clinical Review Status
Clinical + legal review required before publishing